Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
05/2003
05/15/2003WO2003039564A1 Selective targeting of apoptotic cells
05/15/2003WO2003039563A1 Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium
05/15/2003WO2003039553A1 Compositions for treatment of postmenopausal female sexual dysfunction
05/15/2003WO2003039552A1 Combination of pde4 or pde3/4 inhibitor and an anti-rheumatic drug
05/15/2003WO2003039550A1 Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
05/15/2003WO2003039549A2 Selective antibacterial agents
05/15/2003WO2003039545A2 Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
05/15/2003WO2003039544A1 Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
05/15/2003WO2003039543A1 Derivatives of phenoxy-n-'4-(isothiazolidin-1,1-dioxid-2yl)pheny!-valerian- acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors
05/15/2003WO2003039539A2 Use of endothelin receptor antagonists in the treatment of tumour diseases
05/15/2003WO2003039533A1 Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
05/15/2003WO2003039528A1 Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor
05/15/2003WO2003039526A1 Treatment of breast cancer
05/15/2003WO2003039524A1 Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
05/15/2003WO2003039511A1 New use of ethoxylated phytosterols and phytostanols
05/15/2003WO2003039491A2 Novel isoforms of vascular endothelial cell growth inhibitor
05/15/2003WO2003039480A2 Method of treating disorder related to high cholesterol concentration
05/15/2003WO2003039479A2 Polymeric thiol-linked prodrugs
05/15/2003WO2003039478A2 Method and apparatus for the stimulation of hair growth
05/15/2003WO2003039472A2 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
05/15/2003WO2003039469A2 Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
05/15/2003WO2003039466A2 Method of treating estrogen responsive breast cancer
05/15/2003WO2003039464A2 Antimuscarinic aerosol
05/15/2003WO2003039462A2 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
05/15/2003WO2003039460A2 Mitotic kinesin inhibitors
05/15/2003WO2003039455A2 Methods of treating endometreosis
05/15/2003WO2003039452A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003WO2003039451A2 Thiazole pyridazinones as adenosine antagonists
05/15/2003WO2003039449A2 Modulation of dopaminergic neurons
05/15/2003WO2003039446A2 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
05/15/2003WO2003039440A2 Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
05/15/2003WO2003039418A1 Compositions for the treatment of infectious diseases
05/15/2003WO2003039404A2 Methods for treating ocular neovascular diseases
05/15/2003WO2003039344A2 Methods and compositions for correction of cardiac conduction disturbances
05/15/2003WO2003039341A2 Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804
05/15/2003WO2003004509A3 C12 modified erythromycin macrolides and ketolides having antibacterial activity
05/15/2003WO2002092115A3 Method of preventing cell death using segments of neural thread proteins
05/15/2003WO2002088318A3 Lipid-comprising drug delivery complexes and methods for their production
05/15/2003WO2002083179A3 Fusion proteins
05/15/2003WO2002058730A3 Compositions for treatment of ocular neovascularization
05/15/2003WO2002057298A3 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
05/15/2003WO2002056027A3 Regulation of neutral development by daedalos
05/15/2003WO2002055728A3 Compositions and methods for regulating receptor clustering
05/15/2003WO2002048366A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/15/2003WO2002048365A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/15/2003WO2002040533A1 Radiosensitivity enhancers in radiotherapy for cancer and nucleic acids and proteins enhancing radiosensitivity
05/15/2003WO2002040480A3 Crf receptor antagonists and methods relating thereto
05/15/2003WO2002040016A8 Association of calpain inhibitors and reactive oxygen species trapping agents
05/15/2003WO2002038181A3 Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect
05/15/2003WO2002030462A9 Hedgehog antagonists, methods and uses related thereto
05/15/2003WO2002026781A9 Ige receptor antagonists
05/15/2003WO2001080832A3 Administration of a thiol-based chemoprotectant compound
05/15/2003WO2001079173A3 Enamine derivatives as cell adhesion molecules
05/15/2003WO2001071309A3 Methods and reagents for regulation of cellular responses in biological systems
05/15/2003US20030093821 For therapy of human subject diagnosed for predisposition for increased serum cholesterol or LDL cholesterol
05/15/2003US20030093819 Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
05/15/2003US20030092908 Autoimmune diseases; rheumatic diseases; multiple sclerosis; inflammatory bowel disease; immunosuppressants
05/15/2003US20030092771 Inhibitors of transcription factor NF-kappaB
05/15/2003US20030092764 Oxidation resistance
05/15/2003US20030092762 Anti-inflammatory nitro and thia-fatty acids
05/15/2003US20030092759 Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
05/15/2003US20030092756 Antiproliferative agents
05/15/2003US20030092749 Kinase inhibitors; antiinflammatory agents; osteoporosis; anticancer agents
05/15/2003US20030092748 Benzenesulfonamide derivatives and their use as MEK inhibitors
05/15/2003US20030092747 Secretase inhibitor
05/15/2003US20030092744 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
05/15/2003US20030092743 Viricides; aids therapy
05/15/2003US20030092741 Novel alpha adrenergic agents
05/15/2003US20030092738 Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
05/15/2003US20030092736 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
05/15/2003US20030092735 Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome
05/15/2003US20030092732 Eating disorders; dietetics; antiinflammatory agents; autoimmune diseases
05/15/2003US20030092729 Anticancer agents; modulating glycoprotein
05/15/2003US20030092728 Antagonists of MCP-1 function and methods of use thereof
05/15/2003US20030092727 Hydroxamic and carboxylic acid derivatives
05/15/2003US20030092721 Antiinflammatory agents; rheumatic diseases
05/15/2003US20030092719 Methods and kits for treating depression or preventing deterioration of cognitive function
05/15/2003US20030092717 Inhibitors of p38 kinase
05/15/2003US20030092716 Antihypoxic agents
05/15/2003US20030092715 Aryl and biaryl compounds having MCH modulatory activity
05/15/2003US20030092714 Heterocyclic inhibitors of ERK2 and uses thereof
05/15/2003US20030092713 Antiinflammatory agents; antiallergens; psychological disorders
05/15/2003US20030092711 Contraceptives; hormone replacement therapy
05/15/2003US20030092708 Anticholesterol agents; cardiovascular disorders; antilipemic agents
05/15/2003US20030092706 Mixtures of phosphodiesterase inhibitor and antiarthritic agents; bioavailability, side effect reduction
05/15/2003US20030092704 Novel arylglycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds
05/15/2003US20030092703 Caspase inhibitors and uses thereof
05/15/2003US20030092698 N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa
05/15/2003US20030092697 Antidiabetic, antilipemic agents; cardiovascular disorders; anticancer agents
05/15/2003US20030092696 7-Alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors
05/15/2003US20030092692 Alzheimer's and parkinson's disease
05/15/2003US20030092678 Muscle relaxants, controlling immunology, sexual disorders, rheumatic diseases
05/15/2003US20030092677 Glutamate receptor antagonists
05/15/2003US20030092671 Synergistic mixture of low molecular weight heparin and dermatan sulfate; anticoagulants
05/15/2003US20030092645 Cloning, expression, viral and delivery vectors and hosts
05/15/2003US20030092637 Novel compounds
05/15/2003US20030092636 Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium
05/15/2003US20030092631 IGF antagonist peptides
05/15/2003US20030092630 Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases
05/15/2003US20030092629 Inhibitors of memapsin 2 and use thereof
1 ... 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 ... 1564